{"id":60521,"date":"2024-12-19T13:03:16","date_gmt":"2024-12-19T12:03:16","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/"},"modified":"2024-12-19T13:03:16","modified_gmt":"2024-12-19T12:03:16","slug":"castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","title":{"rendered":"Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"
\n

FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL<\/a> #CastleBiosciences<\/a>–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 13, 2024, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 135 employees covering an aggregate of 173,542 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company\u2019s 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe RSUs will vest over four years, with 25% of the shares vesting on the first anniversary of the applicable vesting commencement date, and the balance vesting annually thereafter in three equal installments, subject to the employee\u2019s continued service through each applicable vesting date.<\/p>\n

\nAbout Castle Biosciences<\/b><\/p>\n

\nCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.<\/p>\n

\nCastle\u2019s current portfolio consists of tests for skin cancers, Barrett\u2019s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com<\/a> and connect with us on LinkedIn<\/a>, Facebook<\/a>, X<\/a> and Instagram<\/a>.<\/p>\n

\nDecisionDx-Melanoma, DecisionDx-CMSeq<\/i>, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq<\/i> are trademarks of Castle Biosciences, Inc.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:<\/b>
Camilla Zuckero
\n
czuckero@castlebiosciences.com<\/a><\/p>\n

Media Contact:<\/b>
Allison Marshall
\n
amarshall@castlebiosciences.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CastleBiosciences–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 13, 2024, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 135 employees covering an aggregate of 173,542 shares of common stock as an inducement material … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60521","6":"format-standard","7":"category-industry"},"yoast_head":"\nCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CastleBiosciences–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 13, 2024, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 135 employees covering an aggregate of 173,542 shares of common stock as an inducement material ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-19T12:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20241219028828\/en\/2334815\/22\/CastleLogo2Color.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2024-12-19T12:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\"},\"wordCount\":284,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241219028828\\\/en\\\/2334815\\\/22\\\/CastleLogo2Color.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\",\"name\":\"Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241219028828\\\/en\\\/2334815\\\/22\\\/CastleLogo2Color.jpg\",\"datePublished\":\"2024-12-19T12:03:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241219028828\\\/en\\\/2334815\\\/22\\\/CastleLogo2Color.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241219028828\\\/en\\\/2334815\\\/22\\\/CastleLogo2Color.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","og_locale":"en_US","og_type":"article","og_title":"Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend","og_description":"FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CastleBiosciences–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 13, 2024, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 135 employees covering an aggregate of 173,542 shares of common stock as an inducement material ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","og_site_name":"Pharma Trend","article_published_time":"2024-12-19T12:03:16+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20241219028828\/en\/2334815\/22\/CastleLogo2Color.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2024-12-19T12:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/"},"wordCount":284,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241219028828\/en\/2334815\/22\/CastleLogo2Color.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","url":"https:\/\/pharma-trend.com\/en\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","name":"Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241219028828\/en\/2334815\/22\/CastleLogo2Color.jpg","datePublished":"2024-12-19T12:03:16+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20241219028828\/en\/2334815\/22\/CastleLogo2Color.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20241219028828\/en\/2334815\/22\/CastleLogo2Color.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60521"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60521\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}